IL182591A0 - Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease - Google Patents

Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease

Info

Publication number
IL182591A0
IL182591A0 IL182591A IL18259107A IL182591A0 IL 182591 A0 IL182591 A0 IL 182591A0 IL 182591 A IL182591 A IL 182591A IL 18259107 A IL18259107 A IL 18259107A IL 182591 A0 IL182591 A0 IL 182591A0
Authority
IL
Israel
Prior art keywords
trifluoromethylphenyl
cyano
amide
hydroxy
inflammatory bowel
Prior art date
Application number
IL182591A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of IL182591A0 publication Critical patent/IL182591A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL182591A 2004-10-19 2007-04-16 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease IL182591A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62025504P 2004-10-19 2004-10-19
PCT/US2005/037161 WO2006044741A1 (en) 2004-10-19 2005-10-18 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
IL182591A0 true IL182591A0 (en) 2007-09-20

Family

ID=35636963

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182591A IL182591A0 (en) 2004-10-19 2007-04-16 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease

Country Status (13)

Country Link
US (1) US20070197643A1 (2)
EP (1) EP1804782A1 (2)
JP (1) JP2008517059A (2)
KR (1) KR20070065888A (2)
CN (1) CN101043883A (2)
AU (1) AU2005295511A1 (2)
BR (1) BRPI0518205A (2)
CA (1) CA2584655A1 (2)
IL (1) IL182591A0 (2)
MX (1) MX2007004265A (2)
RU (1) RU2007118691A (2)
SG (1) SG142305A1 (2)
WO (1) WO2006044741A1 (2)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006268238A1 (en) 2005-07-11 2007-01-18 Medtronic Ablation Frontiers Llc Low power tissue ablation system
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2100881A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Pyrimidyl- or pyridinylaminobenzoic acid derivatives
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2277515A1 (en) * 2009-07-10 2011-01-26 Sanofi-Aventis Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
US20120172427A1 (en) * 2009-09-18 2012-07-05 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
WO2012109329A2 (en) 2011-02-08 2012-08-16 Children's Medical Center Corporation Methods for treatment of melanoma
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
CN116725998A (zh) * 2023-07-20 2023-09-12 中国科学技术大学 特立氟胺在抑制nlrp3炎症小体活化中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
EP1071658B1 (en) * 1998-04-17 2004-06-16 Parker Hughes Institute Btk inhibitors and methods for their identification and use
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
EP1372720A4 (en) * 2001-03-02 2006-07-26 Medimmune Inc PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3
EP1381356B1 (en) * 2001-04-05 2008-05-28 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
WO2004024676A1 (de) * 2002-09-06 2004-03-25 Schebo®Biotech Ag Verbindungen zur modulation des glykolyse-enzym-und/oder transaminase-komplexes

Also Published As

Publication number Publication date
CN101043883A (zh) 2007-09-26
AU2005295511A1 (en) 2006-04-27
WO2006044741A1 (en) 2006-04-27
KR20070065888A (ko) 2007-06-25
US20070197643A1 (en) 2007-08-23
MX2007004265A (es) 2008-03-04
SG142305A1 (en) 2008-05-28
JP2008517059A (ja) 2008-05-22
CA2584655A1 (en) 2006-04-27
EP1804782A1 (en) 2007-07-11
RU2007118691A (ru) 2008-11-27
BRPI0518205A (pt) 2008-11-04

Similar Documents

Publication Publication Date Title
IL182591A0 (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
IL152127A0 (en) Probiotic compositions for the treatment of inflammatory bowel disease
PT1592384E (pt) Cop-1 para o tratamento de doenças inflamatórias do intestino
IL181466A0 (en) Pulmonary delivery of inhibitors of phosphodiesterase type 5
EP1558148A4 (en) SURGICAL FASTENING ELEMENT, PARTICULARLY FOR THE TREATMENT OF GASTRO-OESOPHAGEAL REFLUX
IL176584A0 (en) Photoresist compositions and processes of use
HUP0303622A3 (en) Emedies for inflammatory bowel diseases
FR2865377B1 (fr) Materiel d'osteosynthese vertebrale
IL183827A0 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
EP1668024A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INCLUDING INFLAMMATORY SUFFERING
EP1592384A3 (en) Cop 1 for treatment of inflammatory bowel diseases
PT1771201E (pt) Composições e métodos para o tratamento ou prevenção de doenças relacionadas com oxalato
PL375784A1 (en) Use of erythopoietin
ZA200805419B (en) Compositions and methods for preventing or treating inflammatory bowel disease
EP1786428A4 (en) PDE5 INHIBITOR COMPOSITIONS AND METHOD FOR TREATING DISEASE
EP1512415A4 (en) LURE COMPOSITION FOR TREATING AND PREVENTING INFLAMMATORY DISEASES
IL179931A0 (en) Compositions and methods for treatment of cardiovascular disease
EP1838289A4 (en) CONTROLLED RELEASE OF BIOLOGICAL UNITS
GB0124315D0 (en) Inflammatory bowel disease
SG121919A1 (en) Device for cauterising tissue and uses thereof
EP1444983A4 (en) AGENTS FOR THE TREATMENT OF INFLAMMATORY ABDOMINAL DISEASES
EP1954800A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
EP1755635A4 (en) TREATMENT OF INFLAMMATORY RESPIRATORY DISEASE
PL1786759T3 (pl) Nowe pochodne 3,5-seko-4-norcholestanowe i ich zastosowanie
EP1758241A4 (en) IMAGE REMOVAL CIRCUIT